Paracetamol and pregnancy - reminder that taking paracetamol during pregnancy remains safe
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 23 Sept 2025
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Patients should be reminded and reassured that there is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol is recommended as the first-choice pain reliever for pregnant women, used at…
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Patient picks for Alerts, recalls and safety information

Professional
Common problems in pregnancy
Paracetamol use in pregnancy UKTIS - paracetamol monograph; Aug 2023 UKTIS - paracetamol monograph Many studies have looked at neurodevelopmental outcomes following the use of paracetamol - UKTIS makes the following points: The results of these studies are conflicting. The conclusions that can be drawn are limited and a causal association remains.
by Dr Toni Hazell, FRCGP

Professional
Paracetamol poisoning
The Medicines and Healthcare products Regulatory Agency (MHRA) changed the guidelines on management of paracetamol overdose in January 2017. A measurable paracetamol concentration more than 24 hours after ingestion either indicates a very large overdose, or suggests a mistake in time of ingestion, or a staggered ove... Paracetamol overdose during.
by Dr Philippa Vincent, MRCGP

Professional
Field Safety Notices: 12 October 2026 to 16 October 2026
List of Field Safety Notices: 12 October 2026 to 16 October 2026 Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in ....
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
MHRA Safety Roundup: October 2026
Summary of the latest safety advice for medicines and medical device users Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of pr....
by Medicines and Healthcare products Regulatory Agency (MHRA)
%3A%20Don't%20ignore%20suspected%20side%20effects%2C%20report%20them!%20Updates%20to%20the%20Yellow%20Card%20website%20and%20app/og.png)
Professional
#MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app
The annual #MedSafetyWeek campaign is taking place from 2 to 8 November 2026 to promote the importance of reporting side effects from medicines and medical device incidents. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and.
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Field Safety Notices: 26 to 30 October 2026
List of Field Safety Notices from 26 to 30 October 2026. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across.
by Medicines and Healthcare products Regulatory Agency (MHRA)
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Article history
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
23 Sept 2025 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)
More in alerts, recalls and safety information
- Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction
- Class 2 Medicines Recall: Bio Products Laboratory Limited, Rabies, Human normal Immunoglobulin 500IU solution for Injection, EL(26)A/18
- Class 2 Medicines Recall: Crescent Pharma Limited, Ramipril 10mg capsules, EL(26)A/19
- Class 3 Medicines Recall: Aspar Pharmaceuticals Ltd, Ibuprofen 200mg Tablets, Ibucalm 200mg tablets, EL(26)A/07
- NewClass 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/47
- Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets, Chanelle Medical Unlimited Company, EL(25)A/41
- Class 4 Medicines Defect Notification: Teva UK Ltd, Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe, EL(26)A/27
- Class 4 Medicines Defect Notification: Viatris Products Ltd, Arixtra solution for injection, pre-filled syringes, EL(26)A/04
- Dräger Atlan Anaesthesia workstations: risk of ventilator failure (DSI/2026/005)
- NewDuvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat
- Field Safety Notices: 1 May 2026
- Field Safety Notices: 14 to 18 September 2026
- Field Safety Notices: 16-20 February 2026
- Field Safety Notices: 23-27 February 2026
- Field Safety Notices: 24 to 28 August 2026
- Field Safety Notices: 27 to 31 January 2025
- Field Safety Notices: 31 August to 4 September 2026
- MHRA Safety Roundup: September 2025
- Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse
- National Patient Safety Alert: ResMed Astral 100 and 150 Ventilators: Potential for Patient Harm due to Unexpected Interruption of Ventilation Therapy (NatPSA/2026/004/MHRA)


